Skip to main content
PMC home page
British Journal of Clinical Pharmacology logoLink to British Journal of Clinical Pharmacology
. 1987 Jan;23(1):19–27. doi: 10.1111/j.1365-2125.1987.tb03004.x

Detection of sputum eicosanoids in cystic fibrosis and in normal saliva by bioassay and radioimmunoassay.

J T Zakrzewski, N C Barnes, P J Piper, J F Costello
PMCID: PMC1386135  PMID: 3028454

Abstract

We have measured arachidonic acid (AA) metabolites, leukotrienes (LTs) and prostanoids (Ps), in sputum of patients with cystic fibrosis (CF) and in normal saliva using bioassay and radioimmunoassay (RIA). Almost three times as much LTB4 is present in CF extracts compared with slow reacting substances (SRSs). Leukotrienes were not detected in normal saliva. In CF sputum there is a three-fold increase in the level of the vasodilator prostanoid prostaglandin E2 (PGE2) and the stable metabolite of prostacyclin, 6-oxo PGF1 alpha compared with the vasoconstrictor prostaglandin F2 alpha (PGF2 alpha) and thromboxane B2 (TxB2), a hydrolysis product of thromboxane A2. Experiments with BW755c (25 micrograms ml-1, n = 3) indicated that the majority of this activity was not produced during the extraction procedure. The detection of LTs and Ps in sputum of CF patients shows that these substances are present at biologically active concentrations and may contribute to the pathophysiology of this disease.

Full text

PDF
19

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Augstein J., Farmer J. B., Lee T. B., Sheard P., Tattersall M. L. Selective inhibitor of slow reacting substance of anaphylaxis. Nat New Biol. 1973 Oct 17;245(146):215–217. doi: 10.1038/newbio245215a0. [DOI] [PubMed] [Google Scholar]
  2. Bach M. K., Brashler J. R., Brooks C. D., Neerken A. J. Slow reacting substances: comparison of some properties of human lung SRS-A and two distinct fractions from ionophore-induced rat mononuclear cell SRS. J Immunol. 1979 Jan;122(1):160–165. [PubMed] [Google Scholar]
  3. Banschbach M. W., Karam A. G., Love P. K., Hilman B. C. Cystic fibrosis serum promotes [45Ca] uptake by normal human leukocytes. Biochem Biophys Res Commun. 1978 Oct 30;84(4):922–927. doi: 10.1016/0006-291x(78)91671-6. [DOI] [PubMed] [Google Scholar]
  4. Barnes N. C., Piper P. J., Costello J. F. Comparative effects of inhaled leukotriene C4, leukotriene D4, and histamine in normal human subjects. Thorax. 1984 Jul;39(7):500–504. doi: 10.1136/thx.39.7.500. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Bray M. A., Cunningham F. M., Ford-Hutchinson A. W., Smith M. J. Leukotriene B4: a mediator of vascular permeability. Br J Pharmacol. 1981 Mar;72(3):483–486. doi: 10.1111/j.1476-5381.1981.tb11000.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Camp R. D., Coutts A. A., Greaves M. W., Kay A. B., Walport M. J. Responses of human skin to intradermal injection of leukotrienes C4, D4 and B4. Br J Pharmacol. 1983 Nov;80(3):497–502. doi: 10.1111/j.1476-5381.1983.tb10721.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Chase H. P., Long M. A., Lavin M. H. Cystic fibrosis and malnutrition. J Pediatr. 1979 Sep;95(3):337–347. doi: 10.1016/s0022-3476(79)80504-1. [DOI] [PubMed] [Google Scholar]
  8. Cromwell O., Walport M. J., Taylor G. W., Morris H. R., O'Driscoll B. R., Kay A. B. Identification of leukotrienes in the sputum of patients with cystic fibrosis. Adv Prostaglandin Thromboxane Leukot Res. 1982;9:251–257. [PubMed] [Google Scholar]
  9. Dahlén S. E., Hedqvist P., Hammarström S., Samuelsson B. Leukotrienes are potent constrictors of human bronchi. Nature. 1980 Dec 4;288(5790):484–486. doi: 10.1038/288484a0. [DOI] [PubMed] [Google Scholar]
  10. Davis P. B. Autonomic and airway reactivity in obligate heterozygotes for cystic fibrosis. Am Rev Respir Dis. 1984 Jun;129(6):911–914. doi: 10.1164/arrd.1984.129.6.911. [DOI] [PubMed] [Google Scholar]
  11. Ford-Hutchinson A. W., Bray M. A., Doig M. V., Shipley M. E., Smith M. J. Leukotriene B, a potent chemokinetic and aggregating substance released from polymorphonuclear leukocytes. Nature. 1980 Jul 17;286(5770):264–265. doi: 10.1038/286264a0. [DOI] [PubMed] [Google Scholar]
  12. Goetzl E. J. Leukocyte recognition and metabolism of leukotrienes. Fed Proc. 1983 Nov;42(14):3128–3131. [PubMed] [Google Scholar]
  13. Hardy C. C., Robinson C., Tattersfield A. E., Holgate S. T. The bronchoconstrictor effect of inhaled prostaglandin D2 in normal and asthmatic men. N Engl J Med. 1984 Jul 26;311(4):209–213. doi: 10.1056/NEJM198407263110401. [DOI] [PubMed] [Google Scholar]
  14. Hayes E. C., Lombardo D. L., Girard Y., Maycock A. L., Rokach J., Rosenthal A. S., Young R. N., Egan R. W., Zweerink H. J. Measuring leukotrienes of slow reacting substance of anaphylaxis: development of a specific radioimmunoassay. J Immunol. 1983 Jul;131(1):429–433. [PubMed] [Google Scholar]
  15. Higgs G. A., McCall E., Youlten L. J. A chemotactic role for prostaglandins released from polymorphonuclear leucocytes during phagocytosis. Br J Pharmacol. 1975 Apr;53(4):539–546. doi: 10.1111/j.1476-5381.1975.tb07392.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Hsueh W. Prostaglandin biosynthesis in pulmonary macrophages. Am J Pathol. 1979 Oct;97(1):137–148. [PMC free article] [PubMed] [Google Scholar]
  17. Humes J. L., Bonney R. J., Pelus L., Dahlgren M. E., Sadowski S. J., Kuehl F. A., Jr, Davies P. Macrophages synthesis and release prostaglandins in response to inflammatory stimuli. Nature. 1977 Sep 8;269(5624):149–151. doi: 10.1038/269149a0. [DOI] [PubMed] [Google Scholar]
  18. Jose P., Niederhauser U., Piper P. J., Robinson C., Smith A. P. Degradation of porstaglandin F2alpha in the human pulmonary circulation. Thorax. 1976 Dec;31(6):713–719. doi: 10.1136/thx.31.6.713. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Kadowitz P. J., Joiner P. D., Hyman A. L. Physiological and pharmacological roles of prostaglandins. Annu Rev Pharmacol. 1975;15:285–306. doi: 10.1146/annurev.pa.15.040175.001441. [DOI] [PubMed] [Google Scholar]
  20. Lewis R. A., Austen K. F., Drazen J. M., Clark D. A., Marfat A., Corey E. J. Slow reacting substances of anaphylaxis: identification of leukotrienes C-1 and D from human and rat sources. Proc Natl Acad Sci U S A. 1980 Jun;77(6):3710–3714. doi: 10.1073/pnas.77.6.3710. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. MacDermot J., Kelsey C. R., Waddell K. A., Richmond R., Knight R. K., Cole P. J., Dollery C. T., Landon D. N., Blair I. A. Synthesis of leukotriene B4, and prostanoids by human alveolar macrophages: analysis by gas chromatography/mass spectrometry. Prostaglandins. 1984 Feb;27(2):163–179. doi: 10.1016/0090-6980(84)90071-6. [DOI] [PubMed] [Google Scholar]
  22. Moncada S., Vane J. R. Pharmacology and endogenous roles of prostaglandin endoperoxides, thromboxane A2, and prostacyclin. Pharmacol Rev. 1978 Sep;30(3):293–331. [PubMed] [Google Scholar]
  23. Morris H. R., Taylor G. W., Piper P. J., Tippins J. R. Slow-reacting substance of anaphylaxis: studies on purification and characterisation. Agents Actions Suppl. 1979;(6):27–36. doi: 10.1007/978-3-0348-7232-4_3. [DOI] [PubMed] [Google Scholar]
  24. Peck M. J., Piper P. J., Williams T. J. The effect of leukotrienes C4 and D4 on the microvasculature of guinea-pig skin. Prostaglandins. 1981 Feb;21(2):315–321. doi: 10.1016/0090-6980(81)90149-0. [DOI] [PubMed] [Google Scholar]
  25. Piper P. J. Formation and actions of leukotrienes. Physiol Rev. 1984 Apr;64(2):744–761. doi: 10.1152/physrev.1984.64.2.744. [DOI] [PubMed] [Google Scholar]
  26. Piper P. J., Samhoun M. N. Stimulation of arachidonic acid metabolism and generation of thromboxane A2 by leukotrienes B4, C4 and D4 in guinea-pig lung in vitro. Br J Pharmacol. 1982 Oct;77(2):267–275. doi: 10.1111/j.1476-5381.1982.tb09295.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Piper P. J., Tippins J. R. Interaction of leukotrienes with cyclo-oxygenase products in guinea pig isolated trachea. Adv Prostaglandin Thromboxane Leukot Res. 1982;9:183–185. [PubMed] [Google Scholar]
  28. Piper P. J., Tippins J. R., Samhoun M. N., Morris H. R., Taylor G. W., Jones C. M. SRS-A and its formation by the lung. Bull Eur Physiopathol Respir. 1981;17(4):571–583. [PubMed] [Google Scholar]
  29. Rigas B., Lewis R. A., Austen K. F., Corey E. J., Levine L. Identification and quantitation of arachidonic-acid metabolic products in rabbit, rat and human saliva. Arch Oral Biol. 1983;28(11):1031–1035. doi: 10.1016/0003-9969(83)90058-4. [DOI] [PubMed] [Google Scholar]
  30. Salmon J. A., Simmons P. M., Palmer R. M. Synthesis and metabolism of leukotriene B4 in human neutrophils measured by specific radioimmunoassay. FEBS Lett. 1982 Sep 6;146(1):18–22. doi: 10.1016/0014-5793(82)80696-0. [DOI] [PubMed] [Google Scholar]
  31. Samhoun M. N., Piper P. J. The combined use of isolated strips of guinea-pig lung parenchyma and ileum as a sensitive and selective bioassay for leukotriene B4. Prostaglandins. 1984 May;27(5):711–724. doi: 10.1016/0090-6980(84)90009-1. [DOI] [PubMed] [Google Scholar]
  32. Smith A. P., Cuthbert M. F., Dunlop L. S. Effects of inhaled prostaglandins E1, E2, and F2alpha on the airway resistance of healthy and asthmatic man. Clin Sci Mol Med. 1975 May;48(5):421–430. doi: 10.1042/cs0480421. [DOI] [PubMed] [Google Scholar]
  33. Smith M. J., Ford-Hutchinson A. W., Bray M. A. Leukotriene B: a potential mediator of inflammation. J Pharm Pharmacol. 1980 Jul;32(7):517–518. doi: 10.1111/j.2042-7158.1980.tb12985.x. [DOI] [PubMed] [Google Scholar]
  34. Tobin M. J., Maguire O., Reen D., Tempany E., Fitzgerald M. X. Atopy and bronchial reactivity in older patients with cystic fibrosis. Thorax. 1980 Nov;35(11):807–813. doi: 10.1136/thx.35.11.807. [DOI] [PMC free article] [PubMed] [Google Scholar]
  35. Wedmore C. V., Williams T. J. Control of vascular permeability by polymorphonuclear leukocytes in inflammation. Nature. 1981 Feb 19;289(5799):646–650. doi: 10.1038/289646a0. [DOI] [PubMed] [Google Scholar]
  36. Weissmann G. The eicosanoids of asthma. N Engl J Med. 1983 Feb 24;308(8):454–456. doi: 10.1056/NEJM198302243080812. [DOI] [PubMed] [Google Scholar]
  37. Williams T. J. Interactions between prostaglandins, leukotrienes and other mediators of inflammation. Br Med Bull. 1983 Jul;39(3):239–242. doi: 10.1093/oxfordjournals.bmb.a071826. [DOI] [PubMed] [Google Scholar]
  38. Woodward D. F., Weichman B. M., Gill C. A., Wasserman M. A. The effect of synthetic leukotrienes on tracheal microvascular permeability. Prostaglandins. 1983 Jan;25(1):131–142. doi: 10.1016/0090-6980(83)90142-9. [DOI] [PubMed] [Google Scholar]
  39. Woodward H., Horsey B., Bhavanandan V. P., Davidson E. A. Isolation, purification, and properties of respiratory mucus glycoproteins. Biochemistry. 1982 Feb 16;21(4):694–701. doi: 10.1021/bi00533a017. [DOI] [PubMed] [Google Scholar]
  40. Zurier R. B. Prostaglandin release from human polymorphonuclear leukocytes. Adv Prostaglandin Thromboxane Res. 1976;2:815–818. [PubMed] [Google Scholar]

Articles from British Journal of Clinical Pharmacology are provided here courtesy of British Pharmacological Society

RESOURCES